Medicus Pharma Advances Skinject Toward FDA Pivotal Trial for Skin Cancer

Medicus Pharma (NASDAQ: MDCX) has released expanded Phase 2 analysis for its Skinject microneedle therapy, showing promising results in the treatment of basal cell carcinoma, the most common form of skin cancer. The company says the study demonstrated a strong dose response using its 200-microgram microneedle patch, positioning the therapy for an upcoming end-of-Phase-2 meeting with the FDA. Skinject uses a patented dissolvable microneedle array to deliver localized microdoses of chemotherapy directly into skin cancer lesions, potentially reducing the need for invasive surgery. Medicus believes the therapy could offer a more cost-effective and cosmetically favorable alternative for many patients while addressing significant treatment backlogs in dermatology care. #MedicusPharma #MDCX #Biotech #SkinCancer #BasalCellCarcinoma #ClinicalTrials #Oncology #DrugDevelopment #HealthcareInnovation #MedicalResearch #Microneedles #Dermatology #FDA #JaneKing #NewsOut